罗马尼亚和法国公司将自2028年起生产癌症治疗同位素Lutetium-177。 Romanian and French firms will produce cancer-treatment isotope Lutetium-177 starting 2028.

罗马尼亚核电公司和法国Framatome公司已同意在罗马尼亚的Cernavod核电厂生产癌症治疗同位素Lutetium-177。 Romanian nuclear company Nuclearelectrica and French firm Framatome have agreed to produce the cancer-treatment isotope Lutetium-177 at Romania's Cernavodă nuclear plant. 这一伙伴关系旨在增强对治疗包括前列腺癌在内的各种癌症至关重要的Lutetium-177的供应,以支持全球保健需求。 This partnership aims to boost the supply of Lutetium-177, crucial for treating various cancers, including prostate cancer, to support global healthcare needs. 这些公司计划在2028年之前开始生产同位素。 The companies plan to start producing the isotope by 2028.